The clinical trials ran for 68 to 104 weeks for a reason, because the full effect of semaglutide takes time to manifest
Notably, the supplementation of astaxanthin, compared to thermal stress alone, inhibited the expression of inflammatory factors and apoptosis-related genes, including TLR2 , IL8 , EIF4E , IL2RB , CASP3 , and CASP9
Quick Answer: No GLP-1 receptor agonist is currently licensed specifically for fatty liver disease in the UK, but semaglutide and liraglutide show the most promising evidence for reducing hepatic steatosis and inflammation in patients with MASLD/NASH
One of the key challenges was that the receptor has 463 amino acids
This implies that in T2D, there may be a reduction in -cell autophagic flux and if lipotoxicity is the cause, potentially through an obstruction in lysosomal fusion
It is known to help the liver